Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers

Lung Cancer

Volumn 58, Issue 1, 2007, Pages 131-138

  Yanagawa, Naoki ^a   Tamura, Gen ^b   Oizumi, Hiroyuki ^a   Kanauchi, Naoki ^a   Endoh, Makoto ^a   Sadahiro, Mitsuaki ^a   Motoyama, Teiichi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b Yamagata Prefectural Central Hospital   (Japan)

Author keywords

Histological difference; Hypermethylation; Non small cell lung cancer; Prognosis; RASSF1A; RUNX3

Indexed keywords

BIOLOGICAL MARKER; DEATH ASSOCIATED PROTEIN KINASE; FRAGILE HISTIDINE TRIAD PROTEIN; GLYCOPROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN H CADHERIN; PROTEIN P14; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE DURATION; DNA METHYLATION; FEMALE; GENE FREQUENCY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA METHYLATION; FEMALE; GENES, NEOPLASM; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 34548513807     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.05.011     Document Type: Article

References (44)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., and Thun M. Cancer statistics. CA Cancer J Clin 51 (2001) 15-36
2. Kim J.S., Kim J.W., Han J., Shim Y.M., Park J., and Kim D.H. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 66 (2006) 4049-4054
3. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
4. Naruke T., Tsuchiya R., Kondo H., and Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 71 (2001) 1759-1764
5. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1 (1995) 686-692
6. Zochbauer-Muller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., and Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61 (2001) 249-255
7. Yanagawa N., Tamura G., Oizumi H., Takahashi N., Shimazaki Y., and Motoyama T. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 94 (2003) 589-592
8. Toyooka S., Maruyama R., Toyooka K.O., McLerran D., Feng Z., Fukuyama Y., et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103 (2003) 153-160
9. Yanagawa N., Tamura G., Oizumi H., Takahashi N., Shimazaki Y., and Motoyama T. Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. Jpn J Cancer Res 93 (2002) 1107-1113
10. Kim J.S., Han J., Shim Y.M., Park J., and Kim D.H. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer 104 (2005) 1825-1833
11. Waki T., Tamura G., Sato M., and Motoyama T. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 22 (2003) 4128-4133
12. Maruyama R., Sugio K., Yoshino I., Maehara Y., and Gazdar A.F. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 100 (2004) 1472-1477
13. Wang J., Lee J.J., Wang L., Liu D.D., Lu C., Fan Y.H., et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 10 (2004) 6119-6125
14. Nakata S., Sugio K., Uramoto H., Oyama T., Hanagiri T., Morita M., et al. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 106 (2006) 2190-2199
15. Slack A., Bovenzi V., Bigey P., Ivanov M.A., Ramchandani S., Bhattacharya S., et al. Antisense MBD2 gene therapy inhibits tumorigenesis. J Gene Med 4 (2002) 381-389
16. Sobin L.H., and Wittekind C. TNM classification of malignant tumours (1997), Wiley-Liss, New York
17. Travis W.D., Brambilla E., Muller-Hermelink H.K., and Harris C.C. Tumors of lung, pleura, thymus and heart (2004), World Health Organization Classification of Tumors
18. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
19. Zochbauer-Muller S., Fong K.M., Maitra A., Lam S., Geradts J., Ashfaq R., et al. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61 (2001) 3581-3585
20. Toyooka K.O., Toyooka S., Virmani A.K., Sathyanarayana U.G., Euhus D.M., Gilcrease M., et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 61 (2001) 4556-4560
21. Malumbres M., and Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci 3 (1998) d887-d912
22. Hesson L., Dallol A., Minna J.D., Maher E.R., and Latif F. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22 (2003) 947-954
23. Song M.S., Song S.J., Ayad N.G., Chang J.S., Lee J.H., Hong H.K., et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 6 (2004) 129-137
24. Choi N., Son D.S., Song I., Lee H.S., Lim Y.S., Song M.S., et al. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. Int J Cancer 115 (2005) 575-581
25. Tomizawa Y., Kohno T., Kondo H., Otsuka A., Nishioka M., Niki T., et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21,3 in stage I lung adenocarcinoma3 in stage I lung adenocarcinoma. Clin Cancer Res 8 (2002) 2362-2368
26. Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., et al. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer 106 (2003) 45-51
27. Toyooka S., Suzuki M., Maruyama R., Toyooka K.O., Tsukuda K., Fukuyama Y., et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 91 (2004) 771-774
28. Hanai J., Chen L.F., Kanno T., Ohtani-Fujita N., Kim W.Y., Guo W.H., et al. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem 274 (1999) 31577-31582
29. Gergen J.P., and Butler B.A. Isolation of the Drosophila segmentation gene runt and analysis of its expression during embryogenesis. Genes Dev 2 (1988) 1179-1193
30. Bae S.C., Takahashi E., Zhang Y.W., Ogawa E., Shigesada K., Namba Y., et al. Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain. Gene 159 (1995) 245-248
31. Li Q.L., Ito K., Sakakura C., Fukamachi H., Inoue K., Chi X.Z., et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109 (2002) 113-124
32. Kim T.Y., Lee H.J., Hwang K.S., Lee M., Kim J.W., Bang Y.J., et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 84 (2004) 479-484
33. Araki K., Osaki M., Nagahama Y., Hiramatsu T., Nakamura H., Ohgi S., et al. Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis. Cancer Sci 96 (2005) 227-231
34. Sakao Y., Miyamoto H., Sakuraba M., Oh T., Shiomi K., Sonobe S., et al. Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components. Ann Thorac Surg 83 (2007) 209-214
35. Sato K., Tomizawa Y., Iijima H., Saito R., Ishizuka T., Nakajima T., et al. Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 15 (2006) 129-135
36. Li Q.L., Kim H.R., Kim W.J., Choi J.K., Lee Y.H., Kim H.M., et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 314 (2004) 223-228
37. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 5 (1993) 806-811
38. Behrens J. Cell contacts, differentiation, and invasiveness of epithelial cells. Invasion Metastasis 14 (1994-1995) 61-70
39. Bian J., Wang Y., Smith M.R., Kim H., Jacobs C., Jackman J., et al. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 17 (1996) 1805-1811
40. Anand-Apte B., Bao L., Smith R., Iwata K., Olsen B.R., Zetter B., et al. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 74 (1996) 853-862
41. Wild A., Ramaswamy A., Langer P., Celik I., Fendrich V., Chaloupka B., et al. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J Clin Endocrinol Metab 88 (2003) 1367-1373
42. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8923
43. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857-865
44. Karpf A.R., and Jones D.A. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21 (2002) 5496-5503